Beam Therapeutics
BEAM
71 hedge funds and large institutions have $776M invested in Beam Therapeutics in 2020 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 7 closing their positions.
171% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 7
150% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 10
60% more capital invested
Capital invested by funds: $484M → $776M (+$292M)
18% more funds holding
Funds holding: 60 → 71 (+11)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.33% less ownership
Funds ownership: 54.15% → 53.81% (-0.33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$23.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.19M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.99M |
| 4 |
Millennium Management
New York
|
+$2.71M |
| 5 |
BlackRock
New York
|
+$1.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
-$5.41M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$4.76M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$3.16M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.06M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.28M |
BEAM Hedge Fund Activity: Q2 2020 in Review
71 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Beam Therapeutics (BEAM) for Q2 2020, worth a combined $776M — up 60% from $484M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new BEAM positions and 7 closed out — a net gain of 12 holders — while 25 added to existing stakes and 10 trimmed.
The largest buyer was Vanguard Group, adding an estimated $23.1M. The largest seller was Franklin Resources, exiting entirely with an estimated $5.41M sold.
- 71 institutional investors held Beam Therapeutics (BEAM) as of Q2 2020, up from 60 in Q1 2020.
- Funds reported $776M of Beam Therapeutics stock for Q2 2020, up 60% quarter-over-quarter.
- 19 funds opened new Beam Therapeutics positions in Q2 2020 and 7 closed out, a net change of +12 holders.
- The largest Beam Therapeutics buyer in Q2 2020 was Vanguard Group, an estimated $23.1M added.
- The largest Beam Therapeutics seller in Q2 2020 was Franklin Resources, an estimated $5.41M sold.
Based on aggregated 13F filings for Q2 2020.